Early Results of the UK REVIVE Trial for Ex-Vivo Liver Warm Blood Perfusion of DCD and DBD Livers Using the Portable Organ Care System (OCS™) Liver Technology.
Hepatobiliary and Transplant Surgery, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Meeting: 2017 American Transplant Congress
Abstract number: 280
Keywords: Liver preservation, Liver transplantation, Machine preservation, Pulsatile preservation
Session Information
Session Name: Concurrent Session: Organ Perfusion Strategies
Session Type: Concurrent Session
Date: Monday, May 1, 2017
Session Time: 2:30pm-4:00pm
Presentation Time: 3:30pm-3:42pm
Location: E353C
Purpose:TheOCS Liver REVIVE Trial is a single-arm prospective trial to evaluate the safety and performance of OCS™ Liver system to preserve and assess DCD and DBD donor livers for transplantation.
Methods: A total of 25 liver transplant recipients will enrolled into the trial. Donor inclusion criteria: age ≥18 years old; or total cross clamp time ≥6 hours; or DCD ≤60 years old; or ≤50% macrosteatosis. Donor exclusions: living or split donors; or severe liver injury. Recipient inclusion criteria: age ≥ 18 years; registered male or female primary liver transplant candidate; signed written informed consent for the trial. Recipient exclusions: acute, fulminant liver failure; prior transplants; multi-organ transplant; ventilator dependence at time of transplantation. Short-Term endpoints include incidence of EAD within 7 days post-transplant, patient and graft survival at day-30 post-transplant. Length of initial post‐transplant ICU stay and hospital stay. Safety will be assessed by Incidence device related loss of an organ.
Results: to-date, 11 patients were enrolled in the REVIVE trial. Total cross clamp time was 541.3 ± 61.8 mins ranged from 477-636 mins, perfusion time on the OCS was 391.5± 54.5 ranged from 342 – 518 min, 50% of the donors was DCD. All livers were safely perfused and demonstrated normal physiologic functions while on the OCS Liver system, producing bile with stable perfusion parameters, and trending down lactate from 6.9 ± 2.8 mmol/L to 1.6 ± 1.0 mmol/L. All livers preserved on OCS system were successfully transplanted. Incidence of EAD was 2/11 patients (18%) 30 days survival is 100%. No LGR SAEs. Patients and graft survival at hospital discharge and 30 days post-transplantation was 100%. ICU stay 33.5±21 hours and total hospital stay 8.4±2.6 days
Conclusion: The portable OCS Liver system has demonstrated safety and reliability to preserved donor livers. The early clinical outcomes in DCD and DBD liver transplantation is encouraging.
CITATION INFORMATION: Vijayanand D, Zahreldeen F, Kingston J, Farid S, Mdlongwa T, Ramsden A, Willis S, Moriarty C, Attia M. Early Results of the UK REVIVE Trial for Ex-Vivo Liver Warm Blood Perfusion of DCD and DBD Livers Using the Portable Organ Care System (OCS™) Liver Technology. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Vijayanand D, Zahreldeen F, Kingston J, Farid S, Mdlongwa T, Ramsden A, Willis S, Moriarty C, Attia M. Early Results of the UK REVIVE Trial for Ex-Vivo Liver Warm Blood Perfusion of DCD and DBD Livers Using the Portable Organ Care System (OCS™) Liver Technology. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/early-results-of-the-uk-revive-trial-for-ex-vivo-liver-warm-blood-perfusion-of-dcd-and-dbd-livers-using-the-portable-organ-care-system-ocs-liver-technology/. Accessed May 16, 2025.« Back to 2017 American Transplant Congress